BIOHAVEN LTD · Data as of 2026-09-08
2H 2026
• Opakalim, the lead candidate from Biohaven's Kv7 platform, is a next-generation, selective Kv7.2/7.3 potassium channel activator currently in Phase 2/3 development for focal epilepsy, with topline results from the RISE3 trial expected in 2H 2026.Source filing
H2 2026
Topline results for the Phase 2 proof-of-concept study are expected in the second half of 2026.Source filing
Oct 23–Oct 27
In July 2026, the Company announced that new data on BHV-1530, its FGFR3-directed antibody-drug conjugate (ADC) using a novel topoisomerase I (TopoIx) payload, will be presented at the ESMO Congress 2026.Source filing